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oral neonatal antibiotic treatment 
perturbs gut microbiota and 
aggravates central nervous system 
autoimmunity in Dark Agouti rats
suzana stanisavljević1, Aleksa Čepić2, svetlana Bojić3, Katarina Veljović2, sanja Mihajlović2, 
Neda Đedović1, Bojan Jevtić1, Miljana Momčilović1, Milica Lazarević1, Marija Mostarica 
stojković4, Đorđe Miljković1 & Nataša Golić2
Gut microbiota dysbiosis has been considered the essential element in the pathogenesis of multiple 
sclerosis and its animal model, experimental autoimmune encephalomyelitis (eAe). Antibiotics were 
administered orally to Dark Agouti (DA) rats early in their life with the aim of perturbing gut microbiota 
and investigating the effects of such intervention on the course of EAE. As a result, the diversity of the 
gut microbiota was reduced under the influence of antibiotics. Mainly, Firmicutes and Actinobacteria 
were replaced by Proteobacteria and Bacteroidetes, while decreased proportions of Clostridia and 
Bacilli classes were accompanied by an increase in Gamma-Proteobacteria in antibiotic-treated animals. 
Interestingly, a notable decrease in the Helicobacteraceae, Spirochaetaceae and Turicibacteriaceae was 
scored in antibiotic-treated groups. Also, levels of short chain fatty acids were reduced in the faeces of 
antibiotic-treated rats. Consequently, aggravation of eAe, paralleled with stronger immune response 
in lymph nodes draining the site of immunization, and increased inflammation within the CNS, were 
observed in antibiotic-treated DA rats. thus, the alteration of gut microbiota leads to an escalation of 
CNs-directed autoimmunity in DA rats. the results of this study indicate that antibiotic use in early life 
may have subsequent unfavourable effects on the regulation of the immune system.
The intestinal microbiota has become increasingly appreciated as an important, if not the major external factor of 
immune response regulation1,2. A stable gut microbiota which is in balance with gut-associated lymphoid tissue 
(GALT) is a prerequisite for immune homeostasis1. The ratio between effector T helper (Th) cells and regulatory 
T (Treg) cells determines the inflammatory vs. regulatory milieu in the GALT, while the intestinal microbiota has 
a profound influence on Th/Treg balance3. Disturbance of the equilibrium predisposes one to various diseases3, 
including autoimmunity directed against the central nervous system (CNS), as observed in multiple sclerosis and 
its animal model, experimental autoimmune encephalomyelitis (EAE)4. It has been also shown that encephalito-
genic cells migrating into the GALT can be restrained there, expelled into gut lumen and even transformed into 
Treg which are effective against CNS autoimmunity5,6. A balanced intestinal microbiota stimulates a regulatory 
milieu in the GALT through the production and release of various immunomodulatory compounds, including 
short chain fatty acids (SCFA) and polysaccharide A3. Thus, a stable and balanced microbiota seems to be a pre-
requisite for the prevention of various immune-mediated disorders.
Gut microbiota dysbiosis has been observed in various autoimmune disorders, including multiple sclero-
sis, where changes in gut microbiota composition in comparison to healthy subjects have been detected7–10. 
Consequently, gut microbiota dysbiosis has been suggested as an important element of multiple sclerosis patho-
genesis4,11. Although differences in gut microbiota composition between multiple sclerosis patients and healthy 
subjects are evident, it is still not clear if that dysbiosis is a predisposing factor for multiple sclerosis or a conse-
quence of the disease4,11. However, it has recently been shown that transfer of multiple sclerosis patients’ intestinal 
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microbiota potentiates Th1/Th17 over Treg, and enhances spontaneous and active EAE in transgenic and C57Bl/6 
mice, respectively12,13.
Although antibiotics are generally considered safe medications with mild and rare side effects, there is an 
increasing awareness of serious consequences of antibiotic use on gut microbiota14. Indeed, a rising number of 
observational, clinical, and epidemiologic studies focused on children and antibiotics use show that antibiotic 
exposure-related dysbiosis of intestinal microbiota increases the risks for various diseases such as obesity, dia-
betes, inflammatory bowel diseases, celiac disease, allergies and asthma14. Recent studies have shown that global 
antibiotics use increased in the first decade of the 21st century15,16. Importantly, antibiotics are the most commonly 
prescribed paediatric drugs, taking a share of more than 30% of all drugs prescribed to children younger than two 
years17. Specifically, the shares of amoxicillin and azithromycin were 17.1% and 6.3% in year 2010, respectively. 
Therefore, studies that explore the autoimmunity-related effects of antibiotics on intestinal microbiota are valua-
ble for assessing the potential risks of antibiotic use.
Here, EAE-susceptible Dark Agouti (DA) rats were treated with antibiotics early in their lifetime and, as a con-
sequence, their gut microbiota was disturbed and production of SCFA reduced. When challenged with encepha-
litogenic immunization later in their lives, at the time when gut microbiota dysbiosis was no longer evident, the 
rats that had been treated with antibiotics had more severe EAE in comparison to their untreated counterparts. 
The increased severity of EAE was paralleled with increased Th1 and Th17 activity and decreased Treg in immune 
compartments and within the CNS.
Results
Effects of antibiotic treatment on EAE. Gravid DA rats were treated with antibiotics in drinking water 
starting two weeks before giving birth. The treatment continued for an additional four weeks after birth (Fig. 1A). 
Thus, the infants were exposed to antibiotics transferred to milk during nursing and directly through drinking 
water. EAE immunization was performed on 8-week-old rats. DA rats treated with antibiotics experienced more 
severe EAE than control rats (Fig. 1B), as evidenced by longer duration of the disease (Fig. 1C), higher cumulative 
clinical score (c.s.) mean (Fig. 1D), and maximal c.s. (Fig. 1E), higher area under the curve (Fig. 1F), more infil-
trating immune cells per spinal cord section (Fig. 1G) and more cells per infiltrate (Fig. 1H). Also, higher levels of 
IFN-γ and IL-17 were detected in the spinal cords of antibiotic-treated DA rats (Fig. 1I).
Effects of antibiotic treatment on gut microbiota. In order to determine the influence of antibiotic 
treatment on gut microbiota, DGGE analyses of rDNA amplicons obtained by using DNA isolated from faecal 
samples as templates, and universal primers complementary to 16S rRNA regions of Eubacteria, respectively, were 
used (Fig. 2A). The lowest similarity between the antibiotic-treated and control groups was scored in dams and in 
offspring at the time of separation (31.0 ± 2.6% and 31.7 ± 1.6%, respectively), indicating the greatest influence of 
antibiotic treatment on microbiota diversity in the groups. The highest similarity between antibiotic-treated and 
control groups was scored after the EAE induction (72.4 ± 1.7% at 0 d.p.i., 82.2 ± 0.8% at 12 d.p.i. and 78.2 ± 0.7% 
at 31–35 d.p.i.), indicating a recovery of microbiota four weeks after the completion of antibiotic therapy (Fig. 2B). 
Antibiotic treatment led to a significant decrease in bacterial diversity in dams (p<0.001) and offspring at the 
time of separation (p < 0.001), and at the peak of the disease (p<0.01), while no significant differences were 
observed at other time points (Fig. 2C).
On the other hand, a high similarity of DGGE profiles within the groups, both antibiotic-treated and control 
rats, was measured, ranging from 61.0 ± 1.9% to 93.5 ± 2.9% within the control groups and from 71.4 ± 5.8% to 
89.8 ± 1.4% within the antibiotic-treated groups. Therefore, 16S rRNA metagenomic sequencing was performed 
on one randomly chosen faecal sample from each group in order to determine the main microbial players respon-
sible for aggravation of EAE symptoms in DA rats.
The Shannon diversity analysis of 16S rRNA gene metagenomics sequencing revealed differences in 
alpha-diversity between control and antibiotic-treated groups. In accordance with results obtained by DGGE, 
alpha-diversity was lower in antibiotic-treated groups compared to untreated controls (Fig. 3A). Interestingly, 
an increase in alpha diversity was observed at the time of EAE peak, in both antibiotic-treated and untreated 
groups (Fig. 3B). Redundancy analysis (RDA) at the genus level, constrained to antibiotic usage, revealed the 
highest effect of antibiotic use on Hellicobacter. On the other hand, in antibiotic-treated dams higher numbers of 
Proteobacteria (particularly of the Esherichia and Shigela genera) and Bacteroidetes (Bacteroides sp.) was observed 
(Fig. 3C). In addition, samples from antibiotic-treated and control rats were grouped into separate clades regard-
ing their gut microbiota composition, where the antibiotic-treated dams and offspring at the time of separation 
were clustered together. An exemption was observed in the control sample at the time of EAE peak, clustered with 
antibiotic rat samples (Fig. 3D).
Analyses of the relative abundance of detected bacteria within each sample at a phylum level revealed the 
highest dysbiosis of microbiota composition caused by antibiotic treatment in antibiotic-treated dams and off-
spring at the time of separation, where Firmicutes and Actinobacteria were entirely replaced by Proteobacteria and 
Bacteroidetes. Interestingly, the control samples from rats at the time of separation and at EAE peak had a higher 
proportion of Bacteroidetes comparing to other control samples, while the highest proportion of Actinobacteria 
was scored in samples from control rats at the time of EAE induction (Fig. 3E). In addition, at the class level, 
the analysis of relative abundance of detected bacteria within each sample showed specific changes among the 
Firmicute phylum. Namely, a decreased proportion of Clostridia and particularly a decrease in the Bacilli class 
were observed in antibiotic-treated dams. Moreover, this analysis revealed that the Proteobacteria replacing 
Firmucutes in antibiotic-treated offspring (−28 d.p.i.) were mainly Gamma-Proteobacteria (Fig. 3F).
Finally, at the family level the most notable decrease was in the Helicobacteraceae and Spirochaetaceae (p. 
adjusted = 0.0942 and 0.083, respectively) in the antibiotic-treated group, as well as an increase in Bacteroidaceae 
and Enterobacteriaceae families (p. adjusted = 0.0831 and 0.083 respectively). Interestingly, a decrease in the 
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abundance of Turicibacteriaceae in antibiotic-treated rats compared to control groups was scored in all groups 
from dams to the peak of disease. The abundance of Turicibacteriaceae was restored to the control level only from 
31–35 days after immunization (Fig. 3G). On the other hand, at the genus level the most prominent changes were 
noted in Ruminococcus, Bacteroides, CF231, Enterobacter, Treponema and YRC22 genera (p adjusted = 0.0804, 
0.0812, 0.0812, 0.0812, 0.0812 and 0.094 respectively).
Figure 1. Antibiotics aggravate EAE in DA rats. DA rats were untreated (Ctrl) or treated with antibiotics 
(Antb) and immunized with SCH + CFA as depicted in the scheme (A). Clinical score was determined daily 
and various EAE parameters were determined (B–H). Representative micrographs of spinal cord sections are 
presented (I). Cytokine levels were determined in spinal cord homogenates obtained on 14 d.p.i. (J). Data are 
presented as mean +/− SD from 15 rats per group (B–F), from 17 sections per group (G,H) or from 2 rats per 
group (J). *p < 0.05, Antb vs. Ctrl.
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effects of antibiotic treatment on sCFA. Total SCFA concentrations in faecal samples of 
antibiotic-treated and untreated DA rats were analysed. The results revealed significantly lower amounts of SCFA 
detected in antibiotic-treated rats, except at the time of EAE peak (Fig. 4A). Interestingly, the concentration of 
butyric acid was significantly higher in antibiotic-treated rats than in the control animals on the day of immu-
nization (p < 0.05), 12 days after immunization (12 d.p.i.) (p < 0.05) and 31–35 days after the immunization 
(p < 0.05) (Fig. 4B). Similarly, the relative abundance of butyric acid in total SCFA was significantly higher in the 
antibiotic-treated offspring, but not in the dams (Fig. 4C).
Effects of antibiotic treatment on lymph node cells. Lymph nodes draining the site of injection were 
isolated on 3 d.p.i. and 6 d.p.i., while MLN and PP were isolated before the immunization (0 d.p.i.) and at 3 d.p.i. 
and 6 d.p.i. Increased cellularity was observed in PLN at 6 d.p.i. and in MLN on 3 d.p.i. in antibiotic-treated rats 
(Fig. 5A,B), while cellularity of PP remained stable irrespective of the treatment (Fig. 5C). Proportion of Treg was 
increased among PLN, but decreased among MLN and PP at 6 d.p.i. in antibiotic-treated DA rats (Fig. 5D–G).
Spontaneous release of cytokines was measured in PLN cell culture supernatants. Cytokine levels are pre-
sented per whole PLN. There was more IFN-γ at 3 d.p.i., more IL-17 at 3 d.p.i. and 6 d.p.i. and more IL-10 at 6 
d.p.i. in the PLN of antibiotic-treated rats (Fig. 6A-C). Production of cytokines was also measured in PLN cells 
re-stimulated with MBP in vitro. There was more IFN-γ and IL-17 produced at 3 d.p.i., while differences in IL-10 
generation did not reach statistical significance (Fig. 6D–F). Cytokine generation was also measured in MLN 
Figure 2. Effects of antibiotic treatment on DA rat gut microbiota composition. (A) Denaturing gradient gel 
electrophoresis (DGGE) profiles of rDNA amplicons obtained using universal primers (U968-GC and L1401) 
and DNA isolated from the faecal samples of DA rats. Each column represents a DGGE pattern of one rat: 
Ctrl – control animals; Antb – antibiotic-treated rats; dams – time of delivery (7–14 days after the treatment 
with antibiotic was started); −28 d.p.i. - offspring at the time of separation (28 days before the immunization,); 
0 d.p.i. – immunization (SCH + CFA); 12 d.p.i. - EAE peak; 31–35 d.p.i. – recovery. (B) Box-plot diagrams 
of DGGE profiles’ similarity levels based on Dice similarity coefficient. C-C similarity among samples in the 
control group; A-A similarity among samples in the antibiotic-treated group; C-A similarity between samples 
of the control and antibiotic-treated group. (C) Diversity estimated on the basis of the Range-weighted richness 
- Rr from the feces of rats of control and antibiotic-treated rats. Values are presented as arithmetic mean ± SD 
*p < 0.05, **p < 0.01, ***p < 0.001.
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stimulated with ConA, while cytokine mRNA expression was measured in PPC. RT-PCR was performed with 
PPC only, as we were not able to obtain enough PPC to generate cell culture supernatants in adequate quantities 
for ELISA. No difference in the level of the examined cytokines was observed between antibiotic-treated and 
control rats (Fig. 6G–L).
Discussion
Gut microbiota and GALT have manifold interactions that have been shown to have an increasing significance in 
initiation and propagation, but also in regulation of CNS autoimmunity4. Accordingly, changes in gut microbiota 
composition in multiple sclerosis patients in comparison to healthy individuals have been observed7–10. Likewise, 
differences in gut microbiota composition and cellular composition of MLN and PP were observed in EAE-prone 
DA rats in comparison to EAE-resistant Albino Oxford rats18,19. Here, we present evidence that disturbance of 
gut microbiota by antibiotics worsens EAE in DA rats. Although the detrimental effects of antibiotics on chronic 
inflammatory disorders have been reported previously, e.g. in experimental psoriasis20, infection-induced 
Guillain Barré Syndrome in NOD mice21, diabetes in NOD mice22, and experimental systemic sclerosis23, numer-
ous reports have revealed suppressive effects of antibiotic treatment in EAE24–27. Also, protective effects of antibi-
otics were reported in animal models of other neurological diseases, such as Parkinson’s disease28 and Alzheimer’s 
disease29, as well as of various chronic inflammatory diseases, such as rheumatoid arthritis30 and autoimmune 
uveitis31. The results of this study, as well as our recent finding that antibiotics provoke clinically-manifested EAE 
in otherwise EAE-resistant AO rats, show that antibiotic treatment can also be harmful in the case of CNS auto-
immunity32. The contradiction between our results and those of the other groups could be explained by the fact 
that in the work of others adult animals and not pups were treated. A similar discrepancy was already reported 
in experimental psoriasis, as neonatal treatment of mice with antibiotics increased susceptibility to psoriasis, 
while it ameliorated the disease in adult animals20. Also, the difference in the kind of antibiotics applied has to be 
Figure 3. Antibiotics effects on gut microbiota. Samples are obtained from dams – time of delivery (7–14 days 
after the treatment with antibiotic was started); −28 d.p.i. - offspring at the time of separation (28 days before 
the immunization,); 0 d.p.i. – immunization (SCH + CFA); 12 d.p.i. - EAE peak; 31–35 d.p.i. – recovery. (A) 
alpha-diversity plot calculated by Shannon and Simpson between all antibiotic-treated (Antb) and untreated 
(Ctrl) DA rats alpha diversity, all samples resampled to have equal library size, grouped by antibiotic treatment; 
(B) alpha-diversity calculated by Shenon and Simpson between individual antibiotic-treated (antibiotic) and 
untreated (antibiotic free) rats’ groups, all samples resampled to have equal library size, grouped by antibiotic 
treatment. (C) Redundancy analysis (RDA) plot, genus level, constrained on antibiotic usage; (D) Hierarchical 
clustering, weighted unifrac analysis; (E) relative abundances at the phylum level; (F) relative abundances at the 
class level; (G) relative abundance of Turicibacteriaceae.
www.nature.com/scientificreports/
6Scientific RepoRts |           (2019) 9:918  | https://doi.org/10.1038/s41598-018-37505-7
considered, as different antibiotics induce different variations in gut microbiota33. Accordingly, different antibi-
otics were reported to have dissimilar effects on autoimmunity. For instance, neomycin and vancomycin had dif-
ferent effects on gut microbiota and consequently opposite effects on diabetes in NOD mice34. Furthermore, DA 
rats were used in our study, while C57BL/6 mice were used in the previous EAE studies24–27. The subtypes of EAE 
induced in DA rats and C57BL/6 mice are different in many aspects, including antigens and adjuvants used in 
immunization, the course of the disease, and distribution of inflammatory infiltrates within the CNS35. Moreover, 
the gut microbiota of mice and rats are different from each other, as well from human gut microbiota. However, 
detailed comparative analysis of rat and mice gut microbiota show that the rat microbiota profile is more simi-
lar to the human microbiota36. Accordingly, germ-free rats were shown to be more prone to receive and retain 
human gut microbiota than mice37. These data imply an intriguing possibility that human gut microbiota would 
be affected by antibiotics in a similar way as rat gut microbiota. Importantly, germ-free mice are less susceptible 
to EAE induction38. Also, development of spontaneous EAE in transgenic mice is completely absent in germ-free 
mice39. To the best of our knowledge, EAE has not been investigated in germ-free rats, a line of investigation that 
is surely worth pursuing.
Strong dysbiosis caused by antibiotic treatment, both in terms of microbiota diversity and composition was 
observed in this study. Decreased microbiota diversity seems to be one of the most consistent findings in gut 
microbiota dysbiosis and has been repeatedly associated with the modern Western lifestyle and autoimmune 
diseases40. However, the long term effects of antibiotics on microbiota diversity have been only sporadically eval-
uated41. This study was designed to temporally separate intestinal microbiota dysbiosis from the induction of the 
CNS autoimmunity. Rats were receiving antibiotics in the first 4 weeks of their life, while induction of EAE was 
Figure 4. Effect of antibiotic treatment on faecal concentration of short-chain fatty acids (SCFA). Samples are 
obtained from dams – time of delivery (7–14 days after the treatment with antibiotic was started); −28 d.p.i. - 
offspring at the time of separation (28 days before the immunization,); 0 d.p.i. – immunization (SCH + CFA); 
12 d.p.i. - EAE peak; 31–35 d.p.i. – recovery. (A) Concentration of total SCFA from feces of antibiotic-treated 
and untreated rats. (B) Concentration of butyric acid from the feces of antibiotic-treated and untreated rats. (C) 
Concentration of butyric acid versus total SCFA from feces of antibiotic-treated and untreated rats. Values are 
presented as arithmetic mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5. Antibiotics effects on lymph nodes. DA rats were untreated (Ctrl) or treated with antibiotics 
(Antb). Rats were immunized with SCH + CFA. Cellularity of PLN (A), MLN (B) and PP (C) was determined. 
Proportion of Treg among cells of PLN (D), MLN (E) and PP (F) was determined. Cells were gated on live cells 
(R1) and CD4+CD25+ cells (Q2). Representative dot plots of MLN cells obtained on 6 d.p.i. showing gating 
strategy for Treg are presented (G). Data are presented as mean +/− SD from from 6 rats per group (A–F). 
*p < 0.05, Antb vs. Ctrl.
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performed at 8 weeks of age. The effects of the antibiotic treatment on gut microbiota were evident at the time of 
weaning, but they had become discrete by the time of the immunization. This implies that intestinal microbiota 
dysbiosis occurring early in the lifetime, and not the direct effect of antibiotics or gut microbiota dysbiosis at the 
time of CNS autoimmunity initiation, was a contributing factor to EAE pathogenesis. Interestingly, the micro-
biota of antibiotic-treated rats and controls were not significantly different on day 0 post-induction, but the dif-
ference is present 12 days later when microbiota richness is less in antibiotic-treated rats. This result might imply 
that the disease itself impacts the composition of the microbiota. Recent microbiota studies have shown that 
misuse of antibiotics leads to transient or profound loss of the number of microbial species with eventual loss of 
microbial diversity and intestinal domination by pathogenic bacteria42. This effect is even more significant when 
it happens early in life, when the gut microbiota is not fully established43. On the other hand, many other factors 
could also influence gut microbiota composition and diversity. We assume that EAE induction could be one of 
the factors leading to perturbation of the gut microbiota, resulting in increased microbiota diversity in the control 
group. However, it might be assumed that the effect of antibiotics in the early life of antibiotic-treated rats had a 
permanent effect on the diversity of gut microbiota, leading to the inability of the rats to change their gut micro-
biota diversity after EAE induction. Increased diversity in the control group could be the protection mechanism 
by which the organism is trying to overcome the detrimental effects of EAE induction. This mechanism might be 
inefficient in antibiotic-treated rats due to the permanent loss of some important microbial groups, particularly 
Firmicutes and Actinobacteria being replaced by Proteobacteria and Bacteroidetes in antibiotic-treated animals.
Antibiotic-imposed gut microbiota dysbiosis occurring early in life could impact immune responses later in 
life. A balanced microbiota is imperative for maturation of a well-adjusted host immune system, including the 
proper regulation of Th1, Th2, Th17, and regulatory T cells44. The importance of proper microbial colonization for 
immune development was shown previously on germ-free animals, where the absence of gut microbiota caused 
Figure 6. Cytokine production in antibiotic-treated DA rats. DA rats were untreated (Ctrl) or treated with 
antibiotics Antb. Rats were immunized with MBP + CFA for PLN and with SCH + CFA for MLN and PP. 
Spontaneous release of cytokines per PLN (A–C), MBP-stimulated cytokine generation in PLNC (D–F), ConA-
stimulated cytokine production in MLNC (G–I), mRNA expression in PPC (J–L) were determined. Data are 
presented as mean +/− SD from 4 rats per group. *p < 0.05, Antb vs. Ctrl.
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impaired immune function45. Specifically, gut microbiota dysbiosis caused by the early life antibiotic treatment of 
chickens affected the specific antibody response and total IgM and IgY plasma concentrations even months after 
antibiotic treatment cessation, regardless of the recovery of gut microbiota composition. Importantly, the fecal 
microbiota of the antibiotic-treated chickens was restored and resembled that of the control animals two weeks 
after cessation of antibiotic treatment. The authors speculated that lack of lactobacilli and Clostridia (important 
for the maintenance of intestinal homeostasis, enhancement of the innate and adaptive immunity, regulation of 
the T cell- mediated immune responses, and attenuation of the inflammatory processes, together with inhibition 
of the pathogens’ growth) was responsible for the improper immune development and long-term T cell function 
impairment45. In parallel, the results of many clinical studies indicate an association between early life antibiotic 
treatment and the increased risk of developing autoimmune and metabolic diseases such as allergies, inflamma-
tory bowel diseases, obesity, and neurological and brain dysfunction later in life46.
Further, it has recently been shown that gut microbiota dysbiosis during adolescence and young adulthood 
has a profound role in EAE pathogenesis in transgenic mice expressing the MS-associated HLA-DR2a gene and 
an MBP87-99/DR2a-specific 3A6 TCR gene isolated from an MS patient that spontaneously develop EAE47. 
Namely, it was shown that gut dysbiosis during adolescence and young adulthood can overcome immunological 
tolerance to MBP through the increase of complement C3 component and following reduction of Foxp3 and E3 
ubiquitin ligase genes47. Similarly, we present evidence that Treg are limited in rats treated with antibiotics early 
in the lifetime.
It is plausible to assume that the mechanism behind the EAE-promoting effects of antibiotics observed in 
DA rats is the change in microbial diversity and composition, as well as consequent potentiation of Th1- and 
Th17-driven immune response and attenuation of Treg cells. Indeed, increases in IFN-γ and IL-17 production 
were observed in lymphoid tissues of rats treated with antibiotics. Also, decreases in Treg frequency and IL-10 
production were observed in mesenteric lymph nodes and Peyer’s patches. However, Treg frequency and IL-10 
levels were increased in antibiotic-treated rats in the lymph nodes draining the site of immunization 6 days post 
immunization. We have previously observed in various mouse strains that frequency of Treg rises in mesen-
teric lymph nodes but decreases in draining lymph nodes after immunization48. There, it was indicated that the 
observed discrepancy was a consequence of the different migratory properties of Treg cells regulated through 
expression of CCR2 and CCR6 and/or through the proliferative capacity of the cells. Thus, the observed discrep-
ancy in Treg frequency in draining lymph nodes and gut-associated lymphoid tissue in the present study implies 
that proper migratory and proliferative regulation of Treg are disturbed after antibiotic treatment. This assump-
tion is worthy of further investigation.
Importantly, the increased IFN-γ and IL-17 production was also detected within the CNS. This clearly indi-
cates that inappropriate T cell regulation as a consequence of gut microbiota dysbiosis early in the lifetime of rats 
translates to increased CNS autoimmunity in EAE. Still, in future it would be important to assess the effects of the 
antibiotic treatment on EAE spinal cord histopathological data, including the type of cellular infiltrates, demyeli-
nation degree, microglia activation, and astrogliosis.
Despite the large inter-individual differences among the human population, it is becoming recognized 
that a “healthy” human gut microbiota is dominated by balanced proportions of Bacteroidetes, Firmicutes, 
Actinobacteria, Proteobacteria and Verrucomicrobia49. In contrast, the alteration of gut microbiota, called “dysbi-
osis”, has been reported in a number of diseases50. Regarding the gut microbiota composition in multiple sclerosis 
patients, the data have been rather inconsistent. According to Miyake et al.8, decreased abundance of Firmicutes 
(Fecalibacterium, Anaerostipes) and Bacteroidetes (Prevotela) was scored in the gut microbiota of patients 
with relapsing-remitting multiple sclerosis. On the other hand, Chen et al.10 showed decreased Bacteroidetes 
(Parabacteroides and Prevotella) and Actinobacteria (Adlercreutzia and Collinsella) and increased Firmicutes 
(Lactobacillus and Coprobacillus) and Proteobacteria (Pseudomonas, Mycoplana and Haemophilus), while Tremlett 
et al.51 reported only an increase in the abundance of Actinobacteria members in the faecal microbiome of pedi-
atric patients with relapsing-remitting multiple sclerosis.
Moreover, the extensive use of antibiotics has been associated with microbiota dysbiosis and the increased 
risk of inflammatory and autoimmune diseases52. Interestingly, Helicobacter pylori was reported to have protec-
tive effects in patients suffering from multiple sclerosis, suppressing the induction of encephalitogenic Th1 and 
Th17 cells which lead to neuroinflammation50. In line with that, our results indicate that prolonged antibiotic 
treatment causes substantial gut microbiota disruption, followed by the decrease of major bacterial groups impor-
tant for early gut colonization, such as lactobacilli and bifidobacteria. In particular, the results reveal significant 
replacement of Firmicutes (mainly Clostridia and Bacilli, including Lactobacillaceae) and Actinobacteria (par-
ticularly Bifidobacteriaceae) by Proteobacteria (predominantly γ-Proteobacteria, including Enterobacteriaceae) 
and Bacteroidetes in the early life stages of antibiotic-treated DA rats. The presence of Bifidobacterium and 
Lactobacillus has been generally appreciated as beneficial for the host, especially for the colonisation of infants’ 
gut53. On the other hand, Proteobacteria, particularly Enterobacteriaceae, were demonstrated previously as 
the major bacteria in neonatal mice, but those were supressed and replaced by Bacteroidetes and Firmicutes in 
adult mice54. Moreover, the presence of Proteobacteria in adult mice led to increased colonic inflammation54. 
Interestingly, at the genus level among the Bacteroidete phylum, increased abundance of Bacteroides and 
decreased abundance of CF231 (belonging to Prevotelaceae family) in the antibiotic-treated rats was revealed. 
However, one has to be aware that inconsistencies among the previously reported results regarding the abundance 
of various bacteria in multiple sclerosis patients could be related to the phylogenetic level of the changed bacterial 
groups determined in the studies, together with differences in methodology, sequencing techniques, the small 
size of cohorts, lack of longitudinal studies, confounding factors and the geographical origins of the patients10.
In addition, the results of this study reveal a decreased abundance of Turicibacteriaceae in antibiotic-treated 
rats. This is in accordance with our previous results indicating the potential role of Turicibacter sp. in prevention 
of EAE development and the alleviation of the disease’s symptoms18. Importantly, the presence of Turicibacter 
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was positively correlated with the faecal concentration of butyric acid55–58. Butyric acid, as well as other SCFA, has 
been shown to have immunoregulatory effects59,60. The direct exposure of naïve CD4+ T lymphocytes to butyrate 
leads to their differentiation into Treg. Also, butyric acid contributes to the differentiation of Treg cells indirectly 
via tolerogenic activation of dendritic cells60,61. Particular members of gut microbiota participate in the fermenta-
tion of indigestible oligosaccharides, resulting in the production of SCFA62. In accordance with literature data63, 
the results of this study reveal a significant decrease in faecal SCFA concentration in antibiotic-treated DA rats 
compared to control groups. Interestingly, a significant increase of concentration of butyric acid, as well as the 
increase in the relative abundance of butyric acid in total SCFA, was observed in antibiotic-treated rats in com-
parison to control animals. In contrast, decreased concentrations of butyric acid were observed previously after 
oral ampicillin treatment64. However, in a study that determined an increase in SCFA production in lupus patients 
compared to healthy controls65, the authors assumed that gut microbiota dysbiosis contributed to the disease’s 
pathogenesis through metabolic alterations, as the absence of certain bacterial groups enabled colonization of 
other bacterial groups with a different metabolic pattern. Specifically, a reduced Firmicutes/Bacteroides ratio was 
related to increased SCFA fecal levels, particularly the level of propionate. Although butyrate is well known for its 
immunoregulatory properties, e.g. being able to attenuate bowel inflammation59, it was reported that the addition 
of butyrate to drinking water given to mice with dextran sulphate sodium-induced colitis aggravated the symp-
toms of the disease66. It was also shown that butyrate can cause the induction of Th17 response and the produc-
tion of IL-23 in stimulated dendritic cells, exacerbating inflammation66. Moreover, recent results show that higher 
concentrations of butyric acid may stimulate the expression of transcription factor T-bet in T cells, thus inducing 
generation of IFN-γ-producing Tregs or conventional T cells67. Thus, the role of butyrate in mucosal immunity is 
not unequivocal. Also, increased levels of faecal content of butyric acid do not necessarily mean that this SCFA is 
available for gut cells. Indeed, the reduced expression of monocarboxylate transporter 1 (MTC 1) protein and the 
increased levels of butyric acid were observed in patients with inflammatory bowel disease68,69. The authors sug-
gested that the increased concentrations of IFN-γ and TNF led to the negative regulation of expression of MTC 
1, responsible for the transport of butyric acid. The results of our study indicate that the decreased production of 
SCFA by intestinal microbiota, together with potentially decreased transport of butyric acid to the host, could be, 
at least partially, responsible for the decrease in Treg abundance in the GALT and for consequent aggravation of 
EAE. Indeed, a lower proportion of Treg was observed in the mesenteric lymph nodes and Peyer’s patches of rats 
treated with antibiotics. Still, the exact role of SCFA, and butyrate in particular, in development and prognosis of 
autoimmune diseases, such as EAE and multiple sclerosis, requires further elucidation.
Our results suggest that gut microbiota disturbance in early childhood can predispose an individual towards 
CNS autoimmunity that can be provoked by independent stimuli at a later age. Although simultaneous applica-
tion of different antibiotics in high doses and for an extremely long period is not likely to be used in humans, our 
results suggest caution in antibiotic use. Antibiotics are the most commonly used drugs in the paediatric pop-
ulations of Western countries17,70. In fact, their consumption increased by 36% between 2000 and 201015. Also, 
our data call upon epidemiological studies that would explore gut microbiota disturbances as a consequence of 
antibiotic treatment in the early childhood of multiple sclerosis patients. Actually, antibiotic-induced dysbiosis in 
children has already been proposed as a potential predisposing factor for various diseases, including inflamma-
tory bowel disease, obesity and asthma71,72.
In conclusion, antibiotic-induced disturbance of gut microbiota in EAE-prone rats provokes more severe CNS 
autoimmunity. The effect is mediated through disturbance of Th/Treg balance. The results of this study contribute 
to the pool of knowledge regarding the complex relationship between gut microbiota and CNS autoimmunity.
Methods
eAe induction and evaluation. Female DA rats were bred and maintained in the local animal facility 
and their use was approved by the local ethics committee (Institute for Biological Research “Siniša Stanković”, 
N° 04-04/15) in accordance with Directive 2010/63/EU. Three to five rats were kept in the same cage. EAE was 
induced with rat spinal cord homogenate (SCH) in phosphate buffer saline (PBS, 50% w/v) mixed with an equal 
volume of complete Freund’s adjuvant (CFA, Difco, Detroit, MI) supplemented with 5 mg/ml of M. tuberculosis 
H37Ra (Difco). Alternatively, rats were immunized with myelin basic protein (guinea pig MBP, 50 μg/rat, kind 
gift from Professor Alexander Flügel, University of Göttingen, Germany), emulsified with an equal volume of 
CFA supplemented with 5 mg/ml of M. tuberculosis H37Ra. The animals were injected intradermally into hind 
limbs with 100 μL of either emulsion. The rats were monitored daily for clinical signs (c.s.) of EAE: 0, no clinical 
signs; 1, tail atony; 2, hind limb paresis; 3, hind limb paralysis; 4, moribund state or death. Intermediate scores 
were assigned if neurologic signs were of lower severity than typically observed. Cumulative c.s. was calculated as 
sum of daily c.s. Duration was number of days that the clinical signs were observed in each of the rats. Mean c.s. 
was calculated as cumulative c.s. divided by duration. In order to detect inflammatory infiltrates in the CNS of 
immunized animals, hematoxylin and eosin staining was performed. Five micrometres of transversal lumbosa-
cral sections (L1–L5) were cut. Number of infiltrates and cells per infiltrate were counted from histological data 
obtained from 17 sections per group.
Antibiotic treatment. Neosulfox (Sulfadimidine sodium 10% (w/w), neomycin sulfate 6%, oxytetracycline 
hydrochloride 4%, „Fm Pharm“ d.o.o., Subotica), 2.5 g/l Pentrexyl (ampicillin, Galenika, Belgrade, Serbia) were 
applied in drinking water and changed regularly every second day. The treatment of pregnant dams started two 
weeks before the delivery and was introduced to rats gradually from 0.5 g/l to 2.5 g/l. The full dosage was achieved 
one week after the beginning of the treatment. Rats were allowed to drink water with antibiotics ad libitum for 
additional 4 weeks postpartum. Then, rats were separated from mothers and were left without additional treat-
ment till week 8 when they were immunized. Control rats were maintained in parallel. Breeding pairs for antibi-
otic treatment and controls were littermates.
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DGGe analysis, DNA sequencing and microbiome analyses. Faecal samples were collected both 
from antibiotic-treated and control animals, starting from dams at the time of delivery (14 days after the treat-
ment with antibiotic was started) and from the offspring at the time of separation (28 days before the immuni-
zation, −28 d.p.i.), immunization (0 d.p.i.), EAE peak (12 d.p.i.) and recovery (31–35 d.p.i.), as given in Fig. 1A. 
All faecal samples were collected under clean and sterile conditions and immediately frozen at −20 °C. Genomic 
DNA was isolated using the standard protocol from the ZR Faecal DNA MiniPrep™ Kit (Zymo Research, Irvine, 
CA). About 100 to 150 mg of feces was taken from each sample vial under ongoing strict decontamination con-
ditions (personnel using masks and gloves, and decontaminated clean sterile equipment in a sterile ventilated 
hood, Labconco Class II Type B2). All extracted DNA samples were stored at −20 °C. DNA was quantified by 
PicoGreen assay (Invitrogen, ThermoFisher Scientific, Waltham, MA USA). The quantities of obtained DNA 
from all specimens were sufficient for DGGE and 16S-based metagenomic sequencing. DGGE analysis and gel 
manipulation after electrophoresis was entirely performed as described previously73. The universal primer set 
complementary to 16S rRNA, specific for Eubacteria, U-968-GC-f pared with L1401-r, was used74. One sample 
from each antibiotic-treated and control group was used for 16S rRNA metagenomic sequencing, provided by 
Llúcia Martinez-Priego and the team at FISABIO Sequencing and Bioinformatics Service (via Science Exchange).
The processing of the DGGE profiles was done with PyElph software version 1.4. DGGE fingerprints were 
manually scored by the presence or absence of co-migrating bands, independent of intensity. Similarities between 
samples were determined by calculating similarity indices based on the Dice similarity coefficient: Dsc = (2j/
(a + b)) × 100 [%], where j is the number of bands common to samples A and B, and a and b are total number of 
band in samples A and B, respectively. Two identical profiles create a value of 100%, whereas two profiles without 
common bands result in a value of 0%.
HpLC – UV analysis. Extraction of SCFA from faecal samples was performed as described previously75. 
Quantification of SCFA in faecal samples was performed by high- performance liquid chromatography (HPLC) 
using external calibration standards curves method. Four calibration standards were prepared at seven levels of 
concentration ranging from 0.5 mM to 50 mM for acetic acid (AA), propionic acid (PA), butyric acid (BA) and 
internal standard – succinic acid (SA). The calibration curves were constructed by plotting the relative peak area 
versus the molarity of the solution. Faecal concentrations of SCFA were calculated by using the following equa-
tion: SCFA (AA, PA, BA) = (organic acid in faecal sample × 6 × 10−3)/(succinic acid in faecal sample × mass of 
faecal sample) × 1000 [mmol/kg].
The HPLC – UV system consisted of LPG 3400SD HPLC pump, DAD 3000 detector, WPS 3000TSL 
auto sampler and TCC 3000SD column compartment, all from Thermo Scientific (Berda, The Netherlands). 
Chromatographic separation was performed on Hypersil Gold aQ column (150 mm × 4.6 mm) with particle size 
of 3 µm (Thermo Scientific, Breda, The Netherlands). The HPLC column was protected by a guard column of 
the same type. The column was thermostatized at 30 °C. The mobile phase consisted of 20 mM of NaH2PO4 in 
HPLC water (pH adjusted to 2.2 using phosphoric acid) [A] and 100% acetonitrile [B]. The UV detector was set 
at a wavelength of 210 nm. Data processing was performed using Chromeleon 6.8 software (Thermo Scientific).
Isolation of cells, cell culturing and generation of supernatants. Cells of lymph nodes draining 
the site of immunization (popliteal lymph nodes, PLN) were obtained from rats immunized with an emulsion 
made of MBP and CFA. PLN cells (PLNC) were obtained by mechanical disruption. The isolation took place at 
3 and 6 days post immunization (d.p.i.). Mesenteric lymph nodes (MLN) and Peyer’s patches (PP) were isolated 
from non-immunized rats and from rats on 0, 3, 6 d.p.i. For extraction of MLN and PP rats were immunized 
with an emulsion made of SCH and CFA. MLN cells (MLNC) and PP cells (PPC) were obtained by mechanical 
disruption. 5 × 106/ml/well PLNC in 24-well plates (Sarstedt, Nümbrecht, Germany) were cultured in RPMI1640 
medium (PAA Laboratories, Pasching, Austria) supplemented with 2% rat serum. The cells left un-treated for 
spontaneous release of cytokines or re-stimulated with MBP (10 µg/ml). 2.5 × 106/ml MLNC were grown in 
RPMI1640 medium supplemented with 5% fetal calf serum (FCS, PAA Laboratories) and stimulated with con-
canavalin A (ConA, Sigma-Aldrich, 2.5 µg/ml). Cultures lasted for 24 h and subsequently cell culture supernatants 
were collected and kept frozen until assayed. Supernatants were also obtained from spinal cord homogenates. The 
whole spinal cord was homogenized in PBS (w/V at 1 g:2 ml) in a 2 ml Dounce All-Glass Tissue Grinder (DWK 
Life Sciences LLC, Rockwood, TN) by 5 strokes at large clearance and 5 strokes at small clearance. Spinal cord 
homogenate was centrifuged at 10000 g for 30 min and resulting supernatants were collected. For calculation of 
spontaneous cytokine level per PLN the following formula was applied: CxN/5, where C is level of a cytokine 
measured in cell culture supernatant and N is number of cells counted in a PLN (in millions).
Cytofluorimetry. Cells were stained with the following antibodies: PE-conjugated anti-CD4 (OX35, eBiosci-
ence, San Diego, CA), FITC-conjugated anti-CD25 (NDS601, AbD Serotec, Oxford, UK), FoxP3 (FJK-16s, eBio-
science). Appropriate isotype control antibodies were used where necessary to set gates for cell marker positivity. 
Analyses were performed on a CyFlow Space cytometer (Partec, Munster, Germany).
eLIsA. Cytokine concentration in cell culture supernatants was determined by sandwich ELISA using 
MaxiSorp plates (Nunc, Rochild, Denmark). For IL-10 detection Rat IL-10 DuoSet ELISA was used (R&D 
Systems, Minneapolis, MN). For IFN-γ and IL-17 detection the following eBioscience antibodies were used: 
anti-rat IFN-γ (DB1), anti-rat IFN-γ biotinylated rabbit polyclonal, anti-mouse/rat IL-17A (eBio17CK15A5) and 
anti-mouse/rat IL-17A biotinylated (eBio17B7). Samples were analyzed in duplicates and the results were cal-
culated using standard curves made on the basis of known concentrations of the recombinant rat IL-10 (R&D 
Systems), IFN-γ and IL-17 (Peprotech, Rocky Hill, NJ).
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statistical analysis. Two-way ANOVA followed with Student’s t test (two-tailed) or Tukey’s multiple com-
parison test, as appropriate was performed for statistical analysis. A p value less than 0.05 was considered sta-
tistically significant. Area under curve (AUC) was calculated by a numerical integration method based on the 
trapezoidal rule. Raw 16S rRNA sequences were processed in QIIME76,77 with default settings, except for tax-
onomic annotation which was done as suggested previously78. Raw data are submitted to European Nucleotide 
Archive (ENA) (https://www.ebi.ac.uk/ena) under accession number PRJEB26086, secondary accession number 
ERP108059.
OTU picking and taxonomic annotation of clustered sequences was performed in QIIME against both 
GreenGenes database and HIT.db78. All subsequent statistical analysis was done in R79. Shannon index was cal-
culated as a measure of alpha diversity, beta diversity was assessed using weighted unifrac as a distance measure, 
and RDA analysis were all performed in R 3.4.379 using packages ape80 and phyloseq81. Differential expression 
at family and genus level was assessed using ALDEx2 package82 under compositional data analysis paradigm. P 
values were adjusted with Benjamini-Hochberg transformation.
ethics approval and consent to participate. Animal experiments were approved by the local ethics 
committee (Institute for Biological Research “Siniša Stanković”, N° 04-04/15).
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